Patents by Inventor Kevin J. Wilson

Kevin J. Wilson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INHIBITORS OF PROTEIN KINASE A
    Publication number: 20240132490
    Abstract: Described herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof and solvates of any of the foregoing capable of inhibiting protein kinase A and/or its mutants, pharmaceutical compositions comprising at least one of the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, processes for making the compounds, pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, and methods of using the same.
    Type: Application
    Filed: February 1, 2022
    Publication date: April 25, 2024
    Applicant: Blueprint Medicines Corporation
    Inventors: Neil Bifulco, Joseph L. Kim, Stefanie Sandra Schalm, Kevin J. Wilson, Michael Ross Palmer
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230416248
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: November 10, 2021
    Publication date: December 28, 2023
    Inventors: Kevin J. WILSON, Solymar NEGRETTI, Shawn E.R. SCHILLER, Rishi G. VASWANI, David S. HUANG, Johannes H. VOIGT
  • Compositions useful for treating disorders related to KIT
    Patent number: 11827642
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: November 28, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230365560
    Abstract: The present disclosure features compounds of Formula I, or pharmaceutically acceptable salts thereof, and formulations containing the same. Methods of treating BAF complex-related disorders, such as cancer, are also disclosed.
    Type: Application
    Filed: May 11, 2023
    Publication date: November 16, 2023
    Inventors: Shawn E.R. SCHILLER, Solymar NEGRETTI, David S. HUANG, Kevin J. WILSON, Melek Nihan UCISIK, Richard CALDWELL
  • EGFR inhibitors
    Patent number: 11718602
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Grant
    Filed: August 8, 2022
    Date of Patent: August 8, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230149414
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 18, 2023
    Inventors: Neville John ANTHONY, Rishi G. VASWANI, David Simon MILLAN, Shawn E.R. SCHILLER, Kevin J. WILSON
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230145003
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: May 11, 2023
    Inventors: Kevin J. WILSON, Shawn E.R. SCHILLER, Solymar NEGRETTI
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20230129944
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: November 9, 2022
    Publication date: April 27, 2023
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • Inhibitors of activin receptor-like kinase
    Patent number: 11634422
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: May 29, 2020
    Date of Patent: April 25, 2023
    Assignee: Blueprint Medicines Corporation
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian Lewis Hodous, Joseph L. Kim, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230121497
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2021
    Publication date: April 20, 2023
    Inventors: Rishi G. VASWANI, David S. HUANG, Kevin J. WILSON, Shawn E.R. SCHILLER, Neville John ANTHONY
  • COMPOUNDS AND USES THEREOF
    Publication number: 20230079819
    Abstract: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
    Type: Application
    Filed: January 29, 2020
    Publication date: March 16, 2023
    Inventors: Rishi G. VASWANI, Neville John ANTHONY, David Simon MILLAN, Shawn E.R. SCHILLER, Kevin J. WILSON, David S. HUANG
  • EGFR INHIBITORS
    Publication number: 20230056541
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 23, 2023
    Inventors: John Emmerson Campbell, Thomas A. Dineen, Natasja Brooijmans, Jason D. Brubaker, Meredith Suzanne Eno, Joseph L. Kim, Aysegül Özen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson, Christopher De Savi
  • EGFR INHIBITORS
    Publication number: 20230026209
    Abstract: The present disclosure provides a compound represented by structural formula (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.
    Type: Application
    Filed: August 8, 2022
    Publication date: January 26, 2023
    Inventors: Natasja Brooijmans, Jason D. Brubaker, John Emmerson Campbell, Christopher De Savi, Thomas A. Dineen, Meredith Suzanne Eno, Joseph L. Kim, Aysegul Ozen, Emanuele Perola, Brett D. Williams, Douglas Wilson, Kevin J. Wilson
  • INHIBITORS OF ACTIVIN RECEPTOR-LIKE KINASE
    Publication number: 20220315585
    Abstract: Described herein are compounds that inhibit ALK2 and its mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: May 29, 2020
    Publication date: October 6, 2022
    Inventors: Natasja Brooijmans, Jason D. Brubaker, Paul E. Fleming, Brian L. Hodous, Joseph L. Kim, Josh Waetzig, Brett Williams, Douglas Wilson, Kevin J. Wilson, Mark Cronin
  • INHIBITORS OF RET
    Publication number: 20220315560
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: February 11, 2022
    Publication date: October 6, 2022
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • Inhibitors of RET
    Patent number: 11279688
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: March 22, 2022
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • COMPOSITIONS USEFUL FOR TREATING DISORDERS RELATED TO KIT
    Publication number: 20210284645
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Application
    Filed: October 14, 2020
    Publication date: September 16, 2021
    Applicants: Blueprint Medicines Corporation, Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Yulian Zhang
  • Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
    Patent number: 11040979
    Abstract: Compounds and compositions useful for treating disorders related to KIT and PDGFR are described herein.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 22, 2021
    Assignee: Blueprint Medicines Corporation
    Inventors: Brian L. Hodous, Joseph L. Kim, Kevin J. Wilson
  • INHIBITORS OF RET
    Publication number: 20200407341
    Abstract: Described herein are compounds that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions.
    Type: Application
    Filed: January 29, 2020
    Publication date: December 31, 2020
    Inventors: Jason D. Brubaker, Joseph L. Kim, Kevin J. Wilson, Douglas Wilson, Lucian V. DiPietro
  • Compositions useful for treating disorders related to kit
    Patent number: 10807985
    Abstract: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: October 20, 2020
    Assignee: Blueprint Medicines Corporation
    Inventor: Kevin J. Wilson